CDI molecules present various kinds of lipid antigens to T lymphocytes. Human CD1a, CD1b, and CD1c could play an important role in host defense by presenting lipids from microbes. CD1d, by contrast, stimulates a subpopulation of immune regulatory T lymphocytes called NK T cells. NK T cells have been implicated in the immune response to tumors and in the prevention of autoimmune disease. Autologous lipids may be involved in the CD1d-mediated stimulation of NK T cells; they also react to the synthetic lipoglycan, alpha-galactosyl ceramide. Relatively little is known regarding the pathway for the CD1-mediated presentation of lipids. Here we propose a comprehensive study of this pathway, using the NK T cell recognition of alphaGalCer plus mCD1d. We will analyze the intracellular trafficking of antigens and mCD1d molecules, lipoglycan antigen processing, and the in vivo affects on NK T cells of altering the antigen processing pathway or the trafficking of mCD1d. Preliminary data indicate that a disaccharide analog of GalCer requires processing. In the first aim, we will confirm this biochemically, and test a variety of analogs with different carbohydrate and lipid moieties, to determine whether lipid antigen processing is widespread and versatile. In the second aim, we will express mutant mCD1d molecules with restricted intracellular trafficking, and carry out cell fractionation studies to determine where processing and mCD1 antigen binding occur. In the third aim, we will determine the in vivo effect of altering mCD1d intracellular traffic on NK T cell development and function. In the fourth aim, we will explore how alterations in carbohydrate due to deficiency of the enzyme alpha-galactosidase A lead to in vivo deficits in NK T cell number and function. The results from these studies will aid in our understanding of lipid antigen presentation, and they should help in the design of lipid antigen-based vaccines and in attempts to alter immune regulation by stimulating NK T cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI040617-06
Application #
6622223
Study Section
Experimental Immunology Study Section (EI)
Program Officer
Gondre-Lewis, Timothy A
Project Start
1996-12-15
Project End
2006-11-30
Budget Start
2002-12-01
Budget End
2003-11-30
Support Year
6
Fiscal Year
2003
Total Cost
$282,000
Indirect Cost
Name
La Jolla Institute
Department
Type
DUNS #
603880287
City
La Jolla
State
CA
Country
United States
Zip Code
92037
Lawton, Anna P; Prigozy, Theodore I; Brossay, Laurent et al. (2005) The mouse CD1d cytoplasmic tail mediates CD1d trafficking and antigen presentation by adaptor protein 3-dependent and -independent mechanisms. J Immunol 174:3179-86
Sullivan, Barbara A; Nagarajan, Niranjana A; Kronenberg, Mitchell (2005) CD1 and MHC II find different means to the same end. Trends Immunol 26:282-8
Dougan, Stephanie K; Salas, Azucena; Rava, Paul et al. (2005) Microsomal triglyceride transfer protein lipidation and control of CD1d on antigen-presenting cells. J Exp Med 202:529-39
Elewaut, Dirk; Lawton, Anna P; Nagarajan, Niranjana A et al. (2003) The adaptor protein AP-3 is required for CD1d-mediated antigen presentation of glycosphingolipids and development of Valpha14i NKT cells. J Exp Med 198:1133-46
Brossay, L; Tangri, S; Bix, M et al. (1998) Mouse CD1-autoreactive T cells have diverse patterns of reactivity to CD1+ targets. J Immunol 160:3681-8